山山西奈研究人员创建了SMRTS,这是一个针对癌症细胞的MRNA系统,使用针对癌症的微RNA,提高小鼠治疗的准确性和有效性。 Mount Sinai researchers created SMRTS, an mRNA system that targets cancer cells using cancer-specific microRNAs, boosting therapy accuracy and effectiveness in mice.

西奈山的研究人员开发了SMRTS,这是一个MRNA系统,通过使用针对癌症的微RNA来控制基因表达,有选择地激活癌症细胞的治疗。 Researchers at Mount Sinai have developed SMRTS, an mRNA system that selectively activates therapies in cancer cells by using cancer-specific microRNAs to control gene expression. 与传统交付方法不同的是,SMRTS将目标设定逻辑直接植入MRNA,其中一种成分产生酶,摧毁治疗性MRNA,除非受到癌症微RNA的阻拦。 Unlike traditional delivery methods, SMRTS embeds targeting logic directly into the mRNA, with one component producing an enzyme that destroys the therapeutic mRNA unless blocked by cancer microRNAs. 在鼠标模型中,该系统将肿瘤特有基因表达增加141倍,并将非目标效果减少380倍以上,将肿瘤抑制45%,如果与免疫疗法相结合,则高达93%。 In mouse models, the system increased tumor-specific gene expression up to 141-fold and reduced off-target effects by over 380-fold, suppressing tumors by 45% and up to 93% when combined with immunotherapy. 这种方法适应各种疾病,可以扩大MRNA疗法的范围,将疫苗以外的治疗方法扩大到癌症、炎症和代谢紊乱的精密治疗。 The approach, adaptable to various diseases, could expand mRNA therapies beyond vaccines into precision treatments for cancer, inflammation, and metabolic disorders.